Unknown

Dataset Information

0

Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.


ABSTRACT: In this double-blind study, 1143 hypertensive participants with type 2 diabetes and stage 1 or 2 chronic kidney disease (CKD) were randomized to receive combination aliskiren/valsartan 150/160 mg or valsartan 160 mg monotherapy for 2 weeks, with force-titration to 300/320 mg and 320 mg, respectively, for another 6 weeks. Ambulatory blood pressure (ABP), the primary outcome, was available for 665 participants. Reductions from baseline to week 8 in 24-hour ABP were -14.1/-8.7 mm Hg with aliskiren/valsartan vs -10.2/-6.3 mm Hg with valsartan (P<.001). Adverse events were reported in 202 participants (35.2%) taking aliskiren/valsartan and 182 participants (32.2%) taking valsartan. No participant had blood urea nitrogen values>40 mg/dL or serum creatinine values>2.0 mg/dL. There were no confirmed cases of serum potassium values≥6.0 mEq/L. Combination aliskiren/valsartan has additive effects on blood pressure reduction and tolerability similar to valsartan in hypertensive/diabetic participants with early-stage (stages 1 and 2) CKD.

SUBMITTER: Bakris GL 

PROVIDER: S-EPMC8108251 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8108859 | biostudies-literature
| S-EPMC10652658 | biostudies-literature
| S-EPMC8108762 | biostudies-literature
| S-EPMC6089617 | biostudies-literature
| S-EPMC4207330 | biostudies-other
| S-EPMC7045264 | biostudies-literature
| S-EPMC5974697 | biostudies-literature
| S-EPMC9448932 | biostudies-literature
| S-EPMC11307122 | biostudies-literature
| S-EPMC6485836 | biostudies-literature